A Multifunctional Point of- Care Platform to Differentiate HIV Infection from Vaccine Induced Seropositivity

开发区分HIV感染和疫苗诱导血清阳性的诊断方法：该计划的总体目标是支持开发新的血清学和核酸检测方法，以识别HIV感染，同时避免由于疫苗诱导血清阳性（VISP）而导致的假阳性结果，具有高灵敏度和特异性。应开发这些下一代检测方法，以解决艾滋病毒检测的一种或所有应用/适应症，即：(1)实验室检测；(2)护理点和临床实践；(3)自检。该合同旨在开发一种新的诊断平台，该平台可以自动进行HIV-1定性反转录PCR （RT-PCR）测试和两种直接抗体结合试验，以区分HIV-1感染和VISP。

Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be developed to address one or all applications/indications of HIV tests, namely: (1) laboratory based tests; ((2) point-of-care and clinical practices; and (3) self-testing. This contract aims to develop a novel diagnostic platform that automates a HIV-1 qualitative reverse transcription PCR (RT-PCR) test together with two direct antibody binding assays to differentiate HIV-1 infection from VISP.